Logo

Genentech Receives FDA approval for Actemra SC for the Treatment of Active Systemic JIA in patients aged ≥2 yrs.

Share this

Genentech Receives FDA approval for Actemra SC for the Treatment of Active Systemic JIA in patients aged ≥2 yrs.

Shots:

  • The FDA approval is based on P-I JIGSAW-118 (N=51) study assessing PK/PD with appropriate dosage regimen of Actemra SC (aged <17yrs) with range of BWs (weight <30 kg administering 162 mg BID for 10 days; weight ≥30 kg administering 162 mg qw for 52 wks.) in children with sJIA
  • Actemra SC treated patients demonstrated 41% ISRs vs patients treated with Actemra SC for other approved indications. Actemra’s SC efficacy is based on PK disclosure and extrapolation evaluated from Actemra IV & Actemra SC in sJIA & RA patients respectively
  • Actemra can be administered alone or in combination with MTX in sJIA patients. Actemra IV was approved by FDA in 2011 for patients aged ≥2 yrs. with sJIA

/ article | Ref: Genentech | Image: CNN


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions